BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Receptor for advanced glycation endproducts (RAGE)

...azeliragon ( TTP488 ; PF-04494700 ; PF-4494700 ) in Phase III testing for Alzheimer's disease. Dynamis Therapeutics Inc....
BioCentury | May 3, 2012
Distillery Therapeutics

Indication: Cancer

...pretreatment. Next steps include developing antibodies against the specific RAGE domains involved in mediating metastasis. Dynamis Therapeutics Inc.'s...
BioCentury | Mar 24, 2008
Clinical News

Dynamis preclinical data

...Advanced Glycations End (RAGE) products inhibitor lived an average of 256 days longer than controls. Dynamis Therapeutics Inc....
BioCentury | Mar 24, 2008
Clinical News

Dynamis preclinical data

...kidney and retina vs. age-matched controls. The RAGE inhibitor was orally administered for 32 weeks. Dynamis Therapeutics Inc....
BioCentury | Nov 22, 2004
Company News

Cengent, Dynamis deal

...use its Genes to Leads lead identification technology to screen candidates against a target from Dynamis...
...receive upfront payments and is eligible for milestones. Cengent Therapeutics Inc. , San Diego, Calif. Dynamis Therapeutics Inc....
BioCentury | Nov 15, 2004
Company News

Cengent, Dynamis screening deal

...use its Genes to Leads lead identification technology to screen candidates against a target from Dynamis...
BioCentury | Jan 28, 2002
Company News

Dynamis, Development Center for Biotechnology deal

...Dynamis and the center formed a joint venture to develop Dynamis's Dyn 12 small molecule inhibitor...
...enzyme involved in the formation of 3-deoxyglucosone (3DG), which is associated with complications of diabetes. Dynamis...
...compound to prevent diabetes-related diseases and blindness. The center licensed Asian rights to the compound. Dynamis Therapeutics Inc....
BioCentury | Jan 22, 2002
Company News

Dynamis, Taiwan center joint venture

...Dynamis and the Development Center for Biotechnology (Taipei, Taiwan) formed a joint venture to develop Dynamis's...
...enzyme involved in the formation of 3-deoxyglucosone (3DG), which is associated with complications of diabetes. Dynamis...
BioCentury | Apr 9, 2001
Clinical News

Dynamis preclinical data

...involved in the development of Advanced Glycation End products (AGEs), which cause diabetic kidney disease. Dynamis Therapeutics Inc....
BioCentury | Dec 8, 1997
Finance

Disgruntled

The Biotechnology Value Fund was to announce today that it is opposed to the proposed merger between Arris and Sequana . The fund holds a 5 percent stake in ARRS, according to fund manager Mark Lampert....
Items per page:
1 - 10 of 10
BioCentury | Oct 6, 2016
Distillery Therapeutics

Therapeutics: Receptor for advanced glycation endproducts (RAGE)

...azeliragon ( TTP488 ; PF-04494700 ; PF-4494700 ) in Phase III testing for Alzheimer's disease. Dynamis Therapeutics Inc....
BioCentury | May 3, 2012
Distillery Therapeutics

Indication: Cancer

...pretreatment. Next steps include developing antibodies against the specific RAGE domains involved in mediating metastasis. Dynamis Therapeutics Inc.'s...
BioCentury | Mar 24, 2008
Clinical News

Dynamis preclinical data

...Advanced Glycations End (RAGE) products inhibitor lived an average of 256 days longer than controls. Dynamis Therapeutics Inc....
BioCentury | Mar 24, 2008
Clinical News

Dynamis preclinical data

...kidney and retina vs. age-matched controls. The RAGE inhibitor was orally administered for 32 weeks. Dynamis Therapeutics Inc....
BioCentury | Nov 22, 2004
Company News

Cengent, Dynamis deal

...use its Genes to Leads lead identification technology to screen candidates against a target from Dynamis...
...receive upfront payments and is eligible for milestones. Cengent Therapeutics Inc. , San Diego, Calif. Dynamis Therapeutics Inc....
BioCentury | Nov 15, 2004
Company News

Cengent, Dynamis screening deal

...use its Genes to Leads lead identification technology to screen candidates against a target from Dynamis...
BioCentury | Jan 28, 2002
Company News

Dynamis, Development Center for Biotechnology deal

...Dynamis and the center formed a joint venture to develop Dynamis's Dyn 12 small molecule inhibitor...
...enzyme involved in the formation of 3-deoxyglucosone (3DG), which is associated with complications of diabetes. Dynamis...
...compound to prevent diabetes-related diseases and blindness. The center licensed Asian rights to the compound. Dynamis Therapeutics Inc....
BioCentury | Jan 22, 2002
Company News

Dynamis, Taiwan center joint venture

...Dynamis and the Development Center for Biotechnology (Taipei, Taiwan) formed a joint venture to develop Dynamis's...
...enzyme involved in the formation of 3-deoxyglucosone (3DG), which is associated with complications of diabetes. Dynamis...
BioCentury | Apr 9, 2001
Clinical News

Dynamis preclinical data

...involved in the development of Advanced Glycation End products (AGEs), which cause diabetic kidney disease. Dynamis Therapeutics Inc....
BioCentury | Dec 8, 1997
Finance

Disgruntled

The Biotechnology Value Fund was to announce today that it is opposed to the proposed merger between Arris and Sequana . The fund holds a 5 percent stake in ARRS, according to fund manager Mark Lampert....
Items per page:
1 - 10 of 10